Literature DB >> 218990

Correlation between thyrotropin-displacing activity and human thyroid-stimulating activity by immunoglobulins from patients with Graves' disease and other thyroid disorders.

A Sugenoya, A Kidd, V V Row, R Volpé.   

Abstract

Several reports have been published on the anti-TSH receptor antibody in putative autoimmune thyroid disorders using a radioreceptor assay. We have carried out correlative studies between the ability of serum immunoglobulins to displace radiolabeled TSH from the thyroid plasma membrane receptor [TSH-displacing activity (TDA)] and that of actual stimulation of the human thyroid gland [human thyroid-stimulating activity (hTSA)] in Graves' and other thyroid diseases and in control subjects. TDA was assayed by the use of a radioligand technique, while the activation of adenylate cyclase in human thyroid slices was measured as an index of hTSA. The same immunoglobulins were employed for both assays. In this series, positive TDA and hTSA values were found in 70.4% and 81.5% of the samples in active untreated Graves' disease, respectively. Samples from normal persons and from several patients with toxic nodular goiter gave generally negative results in both assays; in a small proportion of patients with either subacute thyroiditis or Hashimoto's thyroiditis, the TDA was positive but hTSA proved to be negative. In Graves' disease (including those patients on propylthiouracil) in remission and treated with 131I, the correlation between TDA and hTSA was not significant (r = 0.309; P greater than 0.1); even when the procedures were compared in the untreated group alone, there was no significant correlation between the two activities (r = 0.309, P greater than 0.1). These studies indicate that 1) significant TDA and hTSA are observed in Graves' disease; nevertheless, the correlation between them is not significant; 2) the hTSA assay appears to be more sensitive and specific than the TDA assay; and 3) TDA may not be synonymous with thyroid stimulation.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 218990     DOI: 10.1210/jcem-48-3-398

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

1.  Clinical course and thyroid stimulating hormone (TSH) receptor antibodies during surgical treatment of Graves' disease.

Authors:  Y Mori; N Matoba; S Miura; N Sakai; Y Taira
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

2.  Anti-bovine thyrotropin autoantibodies in patients with Hashimoto's thyroiditis, subacute thyroiditis, and systemic lupus erythematosus.

Authors:  S Sakata; H Takuno; K Nagai; Y Kimata; H Maekawa; M Yamamoto; N Takeda; Y Ochi; K Miura
Journal:  J Endocrinol Invest       Date:  1991-02       Impact factor: 4.256

Review 3.  Allosteric modulators of glycoprotein hormone receptors: discovery and therapeutic potential.

Authors:  Brian J Arey
Journal:  Endocrine       Date:  2008-10-28       Impact factor: 3.633

4.  Value of thyroid stimulating antibody in the diagnosis of thyroid associated ophthalmopathy of euthyroid patients.

Authors:  K Kazuo; T Fujikado; G Ohmi; J Hosohata; Y Tano
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

5.  Clinical applications of assays for thyrotropin-receptor antibodies in Graves' disease.

Authors:  J Ginsberg; C von Westarp
Journal:  CMAJ       Date:  1986-05-15       Impact factor: 8.262

6.  Changes in thyrotropin binding inhibiting immunoglobulins (TBII) in sera of patients with Graves' disease at the time of relapse or exacerbation.

Authors:  H Uchimura; N Akimoto; T Mitsuhashi; K Kubota; N Kuzuya; Y Imai; H Ikeda; F Matsuzaki; L F Kumagai
Journal:  J Endocrinol Invest       Date:  1986-02       Impact factor: 4.256

7.  Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease.

Authors:  R Hörmann; B Saller; R Müller; K Mann
Journal:  Klin Wochenschr       Date:  1985-12-16

8.  Production, isolation, and characterization of rabbit anti-idiotypic antibodies directed against human antithyrotrophin receptor antibodies.

Authors:  J R Baker; Y G Lukes; K D Burman
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

9.  Monoclonal antibodies to the thyrotropin receptor: the identification of blocking and stimulating antibodies.

Authors:  W A Valente; Z Yavin; E Yavin; E F Grollman; M Schneider; C M Rotella; R Zonefrati; R S Toccafondi; L D Kohn
Journal:  J Endocrinol Invest       Date:  1982 Sep-Oct       Impact factor: 4.256

10.  10 years experience with consecutive measurement of thyrotropin binding inhibiting antibodies (TBIAb).

Authors:  J Hensen; P Kotulla; R Finke; K Badenhoop; K Koppenhagen; H Meinhold; H Schleusener
Journal:  J Endocrinol Invest       Date:  1984-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.